| Literature DB >> 34461278 |
Helen E Heslop1, Edward A Stadtmauer2, John E Levine3, Karen K Ballen4, Yi-Bin Chen5, Amy E DeZern6, Mary Eapen7, Mehdi Hamadani7, Betty K Hamilton8, Parameswaran Hari7, Richard J Jones6, Brent R Logan7, Leslie S Kean9, Eric S Leifer10, Frederick L Locke11, Richard T Maziarz12, Eneida R Nemecek12, Marcelo Pasquini7, Rachel Phelan7, Marcie L Riches13, Bronwen E Shaw7, Mark C Walters14, Amy Foley15, Steven M Devine15, Mary M Horowitz7.
Abstract
In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion, diversity, and access as cross-cutting themes were reviewed. This article summarizes the individual committee reports and their recommendations on the highest priority questions in hematopoietic stem cell transplant and cell therapy to address in multicenter trials.Entities:
Keywords: BMT; Cell Therapy; Clinical Trial
Mesh：
Year: 2021 PMID： 34461278 PMCID： PMC8556300 DOI： 10.1016/j.jtct.2021.08.016
Source DB: PubMed Journal: Transplant Cell Ther ISSN： 2666-6367